Patents Assigned to Genaera Corporation
-
Patent number: 7704710Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: GrantFiled: May 7, 2008Date of Patent: April 27, 2010Assignee: Genaera CorporationInventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Patent number: 7700088Abstract: A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1. When this substitution occurs in both alleles in one individual, it is associated with less evidence of atopic allergy including asthma, fewer abnormal skin test responses, and a lower serum total IgE. Thus, applicant has identified the existence of a non-asthmatic, non-atopic phenotype characterized by methionine at codon 117 when it occurs in both AAF1 gene products in one individual.Type: GrantFiled: March 7, 2007Date of Patent: April 20, 2010Assignee: Genaera CorporationInventors: Roy Clifford Levitt, W. Lee Maloy, U. Prasad Kari, Nicholas C. Nicolaides
-
Patent number: 7504409Abstract: The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.Type: GrantFiled: May 5, 2004Date of Patent: March 17, 2009Assignee: Genaera CorporationInventors: Yuhong Zhou, Roy C. Levitt, Nicholas C. Nicolaides, Steve Jones, Mike McLane
-
Patent number: 7410959Abstract: A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. Various pharmaceutical products may be produced including this pharmaceutical composition. Such pharmaceutical products may be used for the treatment of obesity or diabetes. Methods for using the pharmaceutical compositions also are described. In these methods, various diseases are treated or other body functions are activated or inhibited by administering an effective amount of the pharmaceutical composition. For example, diabetes and obesity may be treated by administering an effective amount of the pharmaceutical compositions. Weight gain, and growth factor production can be inhibited by administering an effective amount of these pharmaceutical compositions.Type: GrantFiled: July 13, 2000Date of Patent: August 12, 2008Assignee: Genaera CorporationInventors: Michael Zasloff, Jon Williams, William Kinney, Mark Anderson, Michael McLane
-
Patent number: 7384767Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: GrantFiled: January 31, 2007Date of Patent: June 10, 2008Assignee: Genaera CorporationInventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Patent number: 7345051Abstract: The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds of Formula II in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases. wherein X is S, N, O or CR; Y is CRR?, O, NR6, CRR?—CRR? or CR?CR; Z is NR6, O, S, CRR? or CRR?—CRR?; R1-R3 are independently selected from the group consisting of H, C1-C8 alkyl, C1-C8 alkoxy, amino, hydroxy, halosubstituted alky and halo; R4 is Q is CR, NR6 or R5 is H or benzyl; R6 is H, C1-C8 alkyl, C1-C8 alkoxy, OH or halo; and R and R? are independently H, C1-C8 alkyl, C1-C8 alkoxy, OH or halo, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 8, 2002Date of Patent: March 18, 2008Assignee: Genaera CorporationInventors: Yuhong Zhou, Roy C. Levitt, Nicholas C. Nicolaides, Steve Jones, Mike McLane
-
Patent number: 7211254Abstract: A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.Type: GrantFiled: February 6, 2004Date of Patent: May 1, 2007Assignee: Genaera CorporationInventors: Kenneth J. Holroyd, Roy C. Levitt, W. Lee Maloy, Jamila Louahed, Mike McLane, Nicholas C. Nicolaides, Yuhong Zhou, Qu Dong
-
Patent number: 7208292Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: GrantFiled: March 9, 2006Date of Patent: April 24, 2007Assignee: Genaera CorporationInventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Patent number: 7192578Abstract: A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1. When this substitution occurs in both alleles in one individual, it is associated with less evidence of atopic allergy including asthma, fewer abnormal skin test responses, and a lower serum total IgE. Thus, applicant has identified the existence of a non-asthmatic, non-atopic phenotype characterized by methionine at codon 117 when it occurs in both AAF1 gene products in one individual.Type: GrantFiled: August 18, 2003Date of Patent: March 20, 2007Assignee: Genaera CorporationInventors: Roy Clifford Levitt, W. Lee Maloy, U. Prasad Kari, Nicholas C. Nicolaides
-
Patent number: 7074778Abstract: This invention relates to methods for treating asthma or allergy in a mammal by administering a 3-aminosteroid compound to a mammal in need thereof. The 3-aminosteroid compound being capable of down regulating the IL-9 pathway and alleviating asthmatic responses to allergen. Exemplary 3-aminosteroid compounds used in the methods of the invention include compounds having the chemical formula (I), wherein X, R1, R2, R3, and R4 groups are as defined herein. The invention also relates to certain novel compounds of formula (I). Moreover, the invention also provides methods for identifying an immunomodulatory 3-aminosteroid compound.Type: GrantFiled: December 11, 2000Date of Patent: July 11, 2006Assignee: Genaera CorporationInventors: Roy C. Levitt, Nicholas C. Nicolaides, William A. Kinney, Steve Jones
-
Patent number: 7056698Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: GrantFiled: December 17, 2002Date of Patent: June 6, 2006Assignee: Genaera CorporationInventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Patent number: 6962909Abstract: Aminosterol compounds are described that are useful as inhibitors of the sodium/proton exchanger (NHE). Methods of using such aminosterols compounds are also enclosed, including those employing compounds that are inhibitors of a spectrum of NHEs as well as those using compounds that are inhibitors of only one specific NHE. Advantageous screening techniques and assays for evaluating a compound's therapeutic activity are also disclosed.Type: GrantFiled: November 2, 2001Date of Patent: November 8, 2005Assignee: Genaera CorporationInventors: Michael Zasloff, Ann Shinnar, William Kinney, Steven Jones
-
Patent number: 6933383Abstract: An efficient method for the synthesis of aminosterol compounds such as squalamine and compound 1436 is described. A method of the invention provides for regioselective oxidation and regioselective sulfonation of a fused ring system. The fused ring base can be, for example, a steroid ring base. The aminosterol compounds are effective as, for example, antibiotics, antiangiogenic agents and NHE3 inhibitors.Type: GrantFiled: October 11, 2002Date of Patent: August 23, 2005Assignee: Genaera CorporationInventors: William A. Kinney, Xuehai Zhang, Ronald Michalak
-
Publication number: 20040254096Abstract: The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.Type: ApplicationFiled: May 5, 2004Publication date: December 16, 2004Applicant: Genaera CorporationInventors: Yuhong Zhou, Roy C. Levitt, Nicholas C. Nicolaides, Steve Jones, Mike McLane
-
Patent number: 6737427Abstract: The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.Type: GrantFiled: January 31, 2001Date of Patent: May 18, 2004Assignee: Genaera CorporationInventors: Yuhong Zhou, Roy C. Levitt, Nicholas C. Nicolaides, Steve Jones, Mike McLane
-
Patent number: 6716603Abstract: A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.Type: GrantFiled: October 16, 2002Date of Patent: April 6, 2004Assignee: Genaera CorporationInventors: Kenneth J. Holroyd, Roy C. Levitt, W. Lee Maloy, Jamila Louahed, Mike McLane, Nicholas C. Nicolaides, Yuhong Zhou, Qu Dong
-
Publication number: 20030236220Abstract: The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.Type: ApplicationFiled: November 8, 2002Publication date: December 25, 2003Applicant: Genaera CorporationInventors: Yuhong Zhou, Roy C Levitt, Nicholas C Nicolaides, Steve Jones, Mike McLane
-
Patent number: 6645492Abstract: A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1. When this substitution occurs in both alleles in one individual, it is associated with less evidence of atopic allergy including asthma, fewer abnormal skin test responses, and a lower serum total IgE. Thus, applicant has identified the existence of a non-asthmatic, non-atopic phenotype characterized by methionine at codon 117 when it occurs in both AAF1 gene products in one individual.Type: GrantFiled: May 4, 2001Date of Patent: November 11, 2003Assignee: Genaera CorporationInventors: Roy Clifford Levitt, W. Lee Maloy, U. Prasad Kari, Nicholas C. Nicolaides
-
Publication number: 20030149287Abstract: Aminosterol compounds are described that are useful as inhibitors of the sodium/proton exchanger (NHE). Methods of using such aminosterols compounds are also enclosed, including those employing compounds that are inhibitors of a spectrum of NHEs as well as those using compounds that are inhibitors of only one specific NHE. Advantageous screening techniques and assays for evaluating a compound's therapeutic activity are also disclosed.Type: ApplicationFiled: November 2, 2001Publication date: August 7, 2003Applicant: Genaera CorporationInventors: Michael Zasloff, Ann Shinnar, William Kinney, Steven Jones
-
Patent number: 6602850Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: GrantFiled: June 16, 2000Date of Patent: August 5, 2003Assignee: Genaera CorporationInventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd